Business description
Amarin Corporation plc develops and commercializes cardiovascular therapeutics, focusing on its product VASCEPA, an omega-3 fatty acid medication for severe hypertriglyceridemia. Operating in the U.S., Europe, Canada, and other regions, Amarin collaborates with Mochida Pharmaceutical for development. Founded in 1989, Amarin is headquartered in Dublin, Ireland.
Management board & Supervisory board
| CEO |
| Aaron Berg |
| Management board |
| Tom Reilly, Jonathan Provoost , Nabil Abadir, David Keenan, Steven Ketchum |
| Supervisory board |
| Aaron Berg, Patrice Bonfiglio, Paul Cohen, M.D., Mark DiPa010, Keith L. Horn, Odysseas Kostas, M.D., Louis Sterling Ill, Diane E. Sullivan, Oliver O'Connor |
Company data
| Name: |
Amarin Corporation plc |
| Address: |
Iconic Offices, The Greenway Block C Ardilaun Court St,Dublin, 112-114 Ireland |
| Phone: |
+353-0-166-99020 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://amarincorp.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
90.40% |
| IPO date: |
- |
Investor relations
| Name: |
Mark Marmur |
| IR phone: |
- |
| IR Fax: |
- |
| IR e-mail: |
PR@amarincorp.com
|
